Journal of Medicinal Chemistry · 2005 · 525 citations · 29 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryEnzymologyMolecular PharmacologyEnzyme InhibitionPotency OptimizationHistone DeacetylasesIndole ChemistryIndole DerivativesMedicinal Chemistry ApplicationsNad+-dependent EnzymesNad-dependent EnzymesSirtuin 1 RegulationTherapeutic Uses
High-throughput screening against the human sirtuin SIRT1 led to the discovery of a series of indoles as potent inhibitors that are selective for SIRT1 over other deacetylases and NAD-processing enzymes. The most potent compounds described herein inhibit SIRT1 with IC50 values of 60-100 nM, representing a 500-fold improvement over previously reported SIRT inhibitors. Preparation of enantiomerically pure indole derivatives allowed for their characterization in vitro and in vivo. Kinetic analyses suggest that these inhibitors bind after the release of nicotinamide from the enzyme and prevent the release of deacetylated peptide and O-acetyl-ADP-ribose, the products of enzyme-catalyzed deacetylation. These SIRT1 inhibitors are low molecular weight, cell-permeable, orally bioavailable, and metabolically stable. These compounds provide chemical tools to study the biology of SIRT1 and to explore therapeutic uses for SIRT1 inhibitors.
29
Stress-Dependent Regulation of FOXO Transcription Factors by the SIRT1 Deacetylase
Anne Brunet, Lora B. Sweeney, James Fitzhugh Sturgill et al. · Science · 2004 · 3.2K citations
Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase
Fan Yeung, Jamie E. Hoberg, C S Ramsey et al. · The EMBO Journal · 2004 · 2.7K citations · Full text
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Homayoun Vaziri, Scott Dessain, Elinor Ng Eaton et al. · Cell · 2001 · 2.6K citations · Full text
The Human Sir2 Ortholog, SIRT2, Is an NAD+-Dependent Tubulin Deacetylase
Brian J. North, Brett Marshall, Margie T. Borra et al. · Molecular Cell · 2003 · 1.5K citations · Full text